中國智能集團(00395.HK)與華康生物(08622.HK)組公司發展電商平台業務
中國智能集團(00395.HK)公布,全資附屬Forever Triumph與華康生物(08622.HK)之全資附屬Nutronic Biomedical成立智能創力,分別持51%及49%權益。
智能創力已發行股本為10萬元,並會於上海成立及註冊成立外商獨資企業,實繳股本為100萬元人民幣,透過跨境電子商務平台或其他(線上、線下或其他形式)平台及渠道於中國及香港開展、發展、經營及以其他方式從事有關(其中包括)銷售、營銷及分銷產品系列及訂約方可能不時協定之其他新產品的業務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.